http://www.envita.com/conditions-we-treat/cancer/immunotherapy/ Immunotherapy for Cancer Treatment is absolutely necessary, and many are lacking it. At Envita, it is not an afterthought but in fact, our focus. The immune system is the first and last defense against cancer, and we believe to be critical for long-term success.

1. Envita's AAIT - a Powerful Immunotherapy for Cancer
Envita's AAIT - a Powerful Immunotherapy for Cancer
AAIT is an acronym for autologous adoptive immune therapy and defines a therapy derived
from a patient’s own blood, which is re-infused during cancer treatment. There are abundant
strategies for immunotherapy and just as many treatments that can be referenced as
“autologous adoptive immunotherapy.” Clearly, not all options are deemed comparable.
Envita’s immunotherapy, AAIT, involves 4 major cell types which include Natural killer
cellsNatural killer T cells, Cytokine-induced killer cells, Cytotoxic T lymphocytes – where the
inclusion of Natural killer cells (NKs) and Natural killer T cells (NKTs) are the predominant focus
of Envita’s AAIT immunotherapy serums.
Natural Killer Cells Important in Cancer Prognosis of Cancer
When NK cell numbers and functionality are low, cancer patients are predisposed to more
aggressive tumor growth. And, as disease progresses, such declines are likely to continue. In
both animal and human clinical trials, we have seen that by restoring NK and NKT function
leads to enhanced cellular immune tumor-response and higher patient survival rates.
Keys to Envita's AAIT Immunotherapy Uniqueness
1) Envita's protocol for AAIT immunotherapy is designed to optimize the expansion of natural
killer cells - the most potent cancer fighting component of the cellular immune system. Most
immunotherapy treatments do not include natural killer cells, and those that do only expand
them in low numbers with little activation.
2) Envita's AAIT immunotherapy protocol takes only 4-5 weeks to grow your cells, so you can

2. begin to experience benefits quickly. Moreover, while other immune therapies administer just
100-200 million cells per treatment, Envita delivers roughly 100 times as many during the
course of your treatment.
3) Multitudes of published studies demonstrate the effects of adoptive immunotherapy for
cancer patients among which Envita has identified and improved upon the best. Company
protocol insists upon the highest-level of procedure for the expansion and application of cells for
each immunotherapy treatment.
4) Unlike other published immune therapies, Envita's AAIT is the only one that can be used as
a “stand-alone.” Moreover, it may also be administered in conjunction with other therapies to
enhance the cells’ effects in patients – an incomparable benefit. Envita's AAIT immunotherapy
is not focused solely on expanding cells in the lab; rather, our goal also includes keeping them
active until reintroduced to the patient’s body.
5) Envita’s AAIT immunotherapy vaccine offers far greater tumor kill, or cytotoxicity than that of
other well-regarded cancer cell vaccines / immunotherapy treatments found throughout the
world. In brief, this means Envita’s activated natural killer cells in AAIT immunotherapy deliver
considerably higher tumor obliteration.
6) In summary, the most direct manner to stack Envita’s proprietary immunotherapy against the
others includes its:
a. Quality - based on cytoxicity (how much tumor the immune system can kill). Envita’s
AAIT immunotherapy consistently delivers “significantly greater tumor kill”.
b. Quantity (how many cells you get back) – Envita’s AAIT immunotherapy comes with
100 times the cell dosage than the others.
c. Sterility (quality control measures) – Envita AAIT immunotherapy is completely
contaminant free.
If you have any questions concerning Envita's AAIT immunotherapy, please consult with
Envita's team of physicians and patient educators. This immunotherapy is offered at Envita’s
international cancer center in Mexico.